BlackRock
BRNS

BlackRock’s Barinthus Biotherapeutics BRNS Stock Holding History

BlackRock’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,485
Closed -$7.72K – 5396
2024
Q3 		$7.72K Buy
+6,485
New +$8.7K ﹤0.01% 5004
2021
Q3 		– Sell
-49,927
Closed -$839K – 5612
2021
Q2 		$839K Buy
+49,927
New +$739K ﹤0.01% 4564

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

BlackRock's BRNS Position: Q4 2024 in Review

BlackRock sold out of Barinthus Biotherapeutics (BRNS) in Q4 2024, closing a stake of 6,485 shares — an estimated $7.72K sold.

BlackRock first reported a position in BRNS in Q2 2021 and held it in 2 quarters. The position peaked at $839K in Q2 2021. 16 funds tracked by Wall St. Rank hold BRNS as of Q4 2024.

  • BlackRock reported no remaining Barinthus Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • BlackRock sold 6,485 Barinthus Biotherapeutics shares in Q4 2024, an estimated $7.72K.
  • BlackRock first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • BlackRock's Barinthus Biotherapeutics position peaked at $839K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q4 2024.

Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.